PBLA - Earnings call transcript Q3 2021 | Panbela Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to Panbela Therapeutics' Third Quarter 2021 Earnings Call [Operator Instructions]. It is my pleasure to turn the floor over to your host, James Carbonara. Sir, the floor is yours.

James Carbonara

Thank you. And once again, welcome to Panbela's third quarter 2021 earnings call. call Chief Simpson, Financial the and Executive on Horvath, Sue Officer. me are Chief Jennifer Officer; With

Before Form on I that forward-looking in turn risks to please the facts Any on of note reports call to statements reports or differ the in as be statements made filed and well has does call other Form over statements may developments. annual subsequently by expressed cause company's on subsequent only are today's to uncertainties reflect made from supplemented this that in detailed XX-Q that this company update the actual supplement filed not as statements. those the and any as call on forward-looking are XX-K and could historical that not made are with report Significant forward-looking Dr. undertake such results company date Simpson, to implied the any or the SEC. statements obligation

turn over to like proceed. would the please Jennifer I to Simpson, of Jennifer, call Now Panbela. CEO Dr.

Jennifer Simpson

will Q&A. for significant joining. recent by it on results, call touching I'll the with then the for review begin and financial and we all then up of Sue QX a will accomplishments. you follow open Thank

pharmacokinetics the Median yet XX.X Ib enrollment as So, patients and months. not SBP-XXX overall current been a gemcitabine Cohort are I'll and of survival Beginning remind two in the when third Phase of with and Since everyone administered XX.X treatment with combination from nab-paclitaxel X for Ia, with has reached. starting metastatic of Cohort with portion clinical patients subjects pancreatic exceeding now recent follow-up ductal tolerability in highlights. safety is quarter in for survival our December trial, XX which complete Phase XXXX, first-line Phase Ib adenocarcinoma. X with and

Additionally, our development focused we on expanding program. clinical remained

between breast, and types, [poly] others, gastric, of cell metabolism, suggest our also as lung being level gears School increased mutation of the Johns immune explored scored colon, tumor relationship Published and research timely with a Hopkins property. across means with glioblastoma, such program intellectual tumor cancers, Shifting are Johns the a being the microenvironment, Hopkins. possibilities with preclinical Medicine. the to which ovarian relationship With University is driven in and also response

approval. indications quarter pancreatic milestones. product, development application path to resources cancer. in which we number shorter the a SBP-XXX. a notification to to efficient like Also producing ready This received to of that we facilitates production patent drive At novel $XX us coverage developing million intend X stock, manufacturing we focused provided in reduces by deal as of study enables SBP-XXX, reduced underwritten steps keep start place Limited, potentially and announced of and time, upon pancreatic synthetic collaboration effective ability its a would International in on we soon expanding our by common close to our patent and During the on in of the company, of services for from with we developed synthesis additional covering for manufacturing investigational This which which claims drug production to as for trial integrated as year expansion process a an cost be commercialize process lastly, as end, of a and the access lead value. new research quicker In Syngene patent important this I patent the XXXX. on an are supply, with benefits, offering many that closed randomized a methods issue QX, into further our including lead point, the provides SBP-XXX to shareholder and manufacture product SBP-XXX adjuvant XX cancer, for a scalable, well to bought and recapping to provides

additional investigation milestones. potential the create of tumor Lastly, may types other preclinical

Johns School partnership and progress across expect In have pancreatic support cancer we Hopkins pre-clinical QX tumors other University to in with development of outside our before year-to-date. the work Medicine of new year-end. pathways We preclinical made conclusion, will data substantial and produce

anticipate We way. metastatic our our to we news this cancer press pancreatic lead have releases of augment progressing further cancer. are patients. achieve indication our will Also, advanced share and ahead milestones along the in we research pancreatic market addressable as through We updates

the by pursuing review We’re indications. indication further value lead to uncovering and Sue it keen I over additional developing our stop and turn to grow and financials. will to shareholder here

Sue Horvath

next manufacturing our compared quarter expenses for loss General of per trial. in share due $X.X you, compared the is is XXXX to XXXX. to the compensation costs $X.XX to the a of the net in was $X.X third investigational we employee the XXXX third XXXX $X.XX million non-cash compared in share or quarter $X.X increase in million million the XXXX were third third diluted products as of Research of diluted per development in $X.X XXXX. decrease in loss lower This Thank in quarter and administrative or produce incremental of million XXXX. and due of clinical versus were million third third million to Net expenses Jennifer. quarter XXXX. quarter of to This $X.X $X.X quarter

quarter liabilities was of assets million a at equivalence sheet million XXXX, million common XX, $X.X underwriting public $X.X operating in offering, current and July no million, $X.X per for proceeds increased and of and inclusive before XXXX. current of which of of of were were million deal currency closed X,XXX,XXX the from shares there commissions. of the XXXX. and on discounts $XX.X loss Our company was $XX.X third September of net the September $X balance of share approximately Total XX, price cash bought loss on Total debt our as to foreign the cash as Xnd the

common million The at diluted by fully purchase of stock $XX.X shares all We includes awards, common options, which million number had stock by insiders including outstanding. to and on outstanding held basis, were diluted held warrants through fully the And shares. Looking XX.X equity are a investors. cap we table.

offering, available following randomized the you invest other Our by wrap-up we Q&A in of indications. open for current the concludes a our please year, to preclinical clinical end believe dollars That trial will remarks and the Can cancer cash us trial, this lines for questions? allow initiate phone operator. prepared the

Operator

coming Garner Your Instructions] first Craig-Hallum. question from Robin [Operator is from

Robin Garner

you Thank there add other second any those you we you to year-end wanted the what collaboration? to patients update in the regarding data the the as a to release that to Is is cohort. big can for by congratulations color the see? Hopkins two nature expect Johns of what I ask, and might

Jennifer Simpson

panels that many activity thank And different warrants are Robin, much moving So types. so that looking program. is, to that into identify to for tumor start at what is, you tumor What a shows been looking development we have at one we across least question.

would trial year. So a next looking part I it be first Phase at the of

that's start. So the

would in of process can won't at If next we development least we year. is you lengthy that one. at the tumor we that a But it's stop anticipate and one first identified into imagine, pretty half goal starting move to the have

Robin Garner

sort that we And of can well? you Is drug see something immuno-oncology might your combinations with all by any as them? at about candidates and end comment

Jennifer Simpson

the of coming It's early next part possible in that may end year. up out

if will. looking you We pre-clinical both programs, at are

it moving for and we'll very end. portion. be have or for depends part that how that the early year more experiments So forward possible are by the whether It's just it'll not on extra into data of

Robin Garner

survival that that are point? two my patients of the for the Cohort learn question, later. Cohort we that Does at at? X. rest Cohort doing anything a look started from excluding can medium second X I the then have study we there can is And in well this very But understand, X

Jennifer Simpson

So if the at at you months. presentation, survival last ASCO the XX.X look median was

what months we months. just at So and with roughly see abraxane two that X.X about gem was than better

I is it that important note patients in there think cohort. were only seven to

So numbers. those are very small

X But pretty we're which think is the I XX Cohort looking us, a you're see in the keeping impressive. at has Cohort important [tal] that using now do we're be little will kind expansion. X an To bit it's towards dose because the For expansion, Cohort that and robust. more same of approximately really patients, certainly X eye and

this So looking program. we're I importantly, which a need to from data nice points think Cohort mature advance to the early and all X the seeing of to forward this it's thing expansion. But see Robin, the and to

the into randomized that looking end. So start your by trial we'll

Operator

Thank you.

question Capital. Butler from from is Your next coming Tony ROTH

Tony Butler

has that time that are if receiving they're just out question or is, first that long still scans. a that they survival amount did my for tumor? X tumor And may have benefit. still the question. the they have, assume is I any -- Did with of In fluctuated? then they It's And Cohort patients

Jennifer Simpson

my you to sure nature back. Unfortunately, do bit guess into it dig little So that yes. just information. is to tumor. cancer actually come But I'd of Tony, but pancreatic more a to to that some does of would have I'm I that is metastatic dig one they have tend level into, the have further give

for I we're months, important have patients, other them we patients, gave tumor know over that there that it's this the population. that allowing be that is things it's essentially, most the think the treatment try. it's thing for an XX patient at they as impressive pretty survival. to us extended fact the But fluctuates, that certainly We the may allowing looking

Tony Butler

Second guess. be Phase question blossom registrational, is at around something I least guess, could into that II trial, could think I randomized, the which I

has versus any this -- care, can thoughts one degree arm study alone So and been but three say XXX? has standard any plus actually to questions, XXX there XXX related you been that so is some there of thought, other use absent in versus pembro bind of previous words a the to

Jennifer Simpson

of given, I we thought to it's the have, that, and we with of so to out structure of Phase standpoint. pretty will will important likely that, deal If the one are combine the to immuno-oncology would what it I to in to is clean, development this like into program we possibly hoping one to think, most preclinical registration, things a a support something given have of make do which it trial. serve, sure from great research that of is keep I we we you tell But look one-to-one drugs. that the

micro most tumor well. sense that most as And in agents environment, space makes identifying then change which so potential we focused and the makes oncology in tumor the subsequently, are sense which on the

Tony Butler

extent Bristol] obviously, The you may were I trial Phase Hopkins. the tumor release that out will, And criteria if you and is asked Would guess might what -- send out press again, important it'd be you relationship you that would conversations think begun and type, second the I information XXXX? Because be send to beneficial Otherwise, some drug. some very you via be, us. costly. the alluded to with And is I actually the you you that [Marco collaboration the give they so question to confidence begin that that all the went next very the be via last involved. in the have tumor release? most what's that might that to press around is again, I that it'd have I tumor And receive with because X assume step, generating through Hopkins of very to as can of

the give? would really information you guess how is question I much around So

Jennifer Simpson

and Tony, yes. that's question, a answer very is the good

is this call, the press people because figure conference most point, it will even how tumor it's begin this got important whether I we're form, to sense very a maybe excited help some out walk we through and out development to why why next release types. in to the makes We a it program some think or

absolutely. So

Operator

and At in thank ladies like are further you, and we program. questions the in for time, Thank today's your gentlemen. this would no you queue, there to participation

time. this disconnect may at lines You your

Panbela Therapeutics (PBLA) 12 Nov 212021 Q3 Earnings call transcript